<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03192696</url>
  </required_header>
  <id_info>
    <org_study_id>P0942</org_study_id>
    <nct_id>NCT03192696</nct_id>
  </id_info>
  <brief_title>Pantheris Atherectomy Treatment of In-Stent Restenosis In Lower Extremity Arteries</brief_title>
  <acronym>INSIGHT</acronym>
  <official_title>INSIGHT: EvaluatIoN of the PantheriS OCT- ImaGing AtHerectomy SysTem For Treatment of In-Stent Restenosis (ISR) Lesions In Lower Extremity Arteries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avinger, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avinger, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, non-randomized, international, multi-center study to evaluate the safety and&#xD;
      effectiveness of the Pantheris OCT-Imaging System to perform atherectomy in In-Stent&#xD;
      Restenotic (ISR) lesions in lower extremity arteries.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, global, single-arm, multi-center study to evaluate the safety and&#xD;
      effectiveness of the Pantheris OCT-Imaging System to perform atherectomy of in-stent&#xD;
      restenotic (ISR) lesions in lower extremity arteries.&#xD;
&#xD;
      The trial will enroll up to 140 subjects diagnosed with peripheral arterial disease of the&#xD;
      lower extremities that have previously been treated with stenting at up to 20 sites. The&#xD;
      primary disease must be located in reference vessel diameter of &gt;3.0mm and ≤7.0mm. Trial&#xD;
      success is focused on safety, including rates of major adverse events through 30 days as&#xD;
      adjudicated by a Clinical Events Committee, and effectiveness, which will be evaluated using&#xD;
      technical success defined as the percent of target lesions that have residual diameter&#xD;
      stenosis &lt;50% post-treatment with the Pantheris device alone as assessed by Angiographic Core&#xD;
      Lab.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from a composite of major adverse events (MAEs) through 30-day follow-up (safety)</measure>
    <time_frame>Day 0 through 30 days post treatment procedure</time_frame>
    <description>The primary safety endpoint is freedom from a composite of major adverse events (MAEs) through 30-day follow-up, as adjudicated by an independent CEC.&#xD;
Individual MAEs include:&#xD;
Cardiovascular-related death;&#xD;
Unplanned, major index limb amputation;&#xD;
Clinically driven target lesion revascularization (TLR);&#xD;
Myocardial infarction; or&#xD;
Device-associated events:&#xD;
Clinically significant perforation,&#xD;
Clinically significant dissection,&#xD;
Clinically significant embolus, or&#xD;
Pseudoaneurysm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Technical success of Pantheris catheter treatment (efficacy) device</measure>
    <time_frame>Day 0</time_frame>
    <description>The primary efficacy endpoint of technical success is defined as the percent of target lesions that have a residual diameter stenosis &lt;50% post the Pantheris device alone, as assessed by an independent Angiographic Core Laboratory.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stent structure freedom from new or worsening stent fracture post Pantheris treatment (safety)</measure>
    <time_frame>Day 0</time_frame>
    <description>Assess the stent for new or worsening stent fracture per comparative Pantheris OCT evaluation pre- and immediately post-procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Effectiveness Endpoint - Freedom from TLR</measure>
    <time_frame>6 months post treatment procedure</time_frame>
    <description>Freedom from TLR at 6 months as assessed by an independent CEC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Effectiveness Endpoint - Procedural Success</measure>
    <time_frame>Day 0</time_frame>
    <description>Procedural success defined as the percent of target lesions that have residual diameter stenosis ≤ 30% post-Pantheris and any other adjunctive therapy, determined by independent Angiographic Core Laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Effectiveness Endpoint - Freedom from TLR</measure>
    <time_frame>12 months post treatment procedure</time_frame>
    <description>Freedom from TLR at 12 months as assessed by an independent CEC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Effectiveness Endpoint - Ankle-Brachial Index</measure>
    <time_frame>30 days, 6 and 12 months post treatment procedure</time_frame>
    <description>Ankle-Brachial Index at 30 days, 6 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Effectiveness Endpoint - Rutherford Classification</measure>
    <time_frame>30 days, 6 and 12 months post treatment procedure</time_frame>
    <description>Rutherford Classification at 30 days, 6 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Effectiveness Endpoint - Use Adjunctive Devices</measure>
    <time_frame>Day 0</time_frame>
    <description>Adjunctive devices (stent placement (bare metal or drug eluting stent), drug eluting balloon or other) utilized during the index procedure.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Treatment Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atherectomy of in-stent restenosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Atherectomy Catheter</intervention_name>
    <description>Treatment of restenotic lesions within stents previously placed within the artery.</description>
    <arm_group_label>Treatment Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is &gt;18 years old;&#xD;
&#xD;
          -  Subject is willing and able to give informed consent;&#xD;
&#xD;
          -  Subject has Rutherford Classification of I-V;&#xD;
&#xD;
          -  Subject presenting with a single Class I, II or III ISR lesion as per Tosaka's&#xD;
             Classification criteria in the lower leg extremities;&#xD;
&#xD;
          -  Target lesion must be &gt;70% stenosed and within a stented segment by angiographic&#xD;
             visual estimation;&#xD;
&#xD;
          -  Reference vessel lumen acceptable for treatment with Pantheris catheter size as per&#xD;
             visual angiographic estimation;&#xD;
&#xD;
          -  Target lesions must be within the stented segment and no more than 3 cm past the&#xD;
             proximal or distal portions of the stent;&#xD;
&#xD;
          -  Target lesion is ≤30 cm in length;&#xD;
&#xD;
          -  Intraluminal crossing of totally occluded lesions prior to atherectomy;&#xD;
&#xD;
          -  At least one patent tibial run-off vessel at baseline; and&#xD;
&#xD;
          -  Subject is capable of meeting requirements and be present at the follow-up clinic&#xD;
             visits at 30 days, 6 months and 12 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is pregnant or breast feeding;&#xD;
&#xD;
          -  Rutherford Class 0 or VI;&#xD;
&#xD;
          -  Severe calcification of the target lesion;&#xD;
&#xD;
          -  Acute ischemia and/or acute thrombosis of the target lesion segment;&#xD;
&#xD;
          -  Target lesion with a covered stent;&#xD;
&#xD;
          -  Target lesion in the iliac artery;&#xD;
&#xD;
          -  Target lesion stenosis &lt;70%;&#xD;
&#xD;
          -  Target lesion &gt;30 cm in length;&#xD;
&#xD;
          -  Subjects with totally occluded stented segments that are not successfully crossed&#xD;
             intraluminally prior to atherectomy treatment;&#xD;
&#xD;
          -  Grade 4 or 5 stent fracture affecting target stent, or where evidence of stent&#xD;
             protrusion into the lumen is noted on angiography in two orthogonal views;&#xD;
&#xD;
          -  Subjects on chronic hemodialysis or creatinine level &gt;2.5 mg/dL;&#xD;
&#xD;
          -  CVA or stroke within 60 days prior to the index procedure;&#xD;
&#xD;
          -  Endovascular or surgical procedure performed on the index limb less than or equal to&#xD;
             30 days prior to the index procedure;&#xD;
&#xD;
          -  Planned endovascular or surgical procedure 30 days after the index procedure;&#xD;
&#xD;
          -  Lesion in the contralateral limb requiring intervention during the index&#xD;
&#xD;
          -  procedure or within 30 days of the index procedure;&#xD;
&#xD;
          -  Known allergy to contrast agents or medications used to perform endovascular&#xD;
&#xD;
          -  intervention that cannot be adequately pre-treated;&#xD;
&#xD;
          -  Subjects in whom anti-platelet, aspirin, anticoagulant, or thrombolytic therapy is&#xD;
             contraindicated;&#xD;
&#xD;
          -  Any thrombolytic therapy within 2 weeks of the index procedure;&#xD;
&#xD;
          -  Any clinical and/or angiographic complication attributed to the use of another device&#xD;
             prior to the insertion of the study device into the subject during the index&#xD;
             procedure;&#xD;
&#xD;
          -  Subjects or their legal guardians who have not or will not sign the Informed Consent;&#xD;
&#xD;
          -  Subjects who are unwilling or unable to comply with the follow-up study&#xD;
&#xD;
          -  requirements; or&#xD;
&#xD;
          -  Participation in any study of an investigational device, medication, biologic or other&#xD;
             agent within 30 days prior to enrollment that is either a cardiovascular study or&#xD;
             could, in the judgment of the investigator, affect the results of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean Janzer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Einstein Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Lawson, PhD</last_name>
    <phone>650-241-7930</phone>
    <email>tlawson@avinger.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Lawson, PhD</last_name>
    <phone>650-241-7030</phone>
    <email>tlawson@avinger.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Bernards Medical Center</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kayla Rubino, LPN</last_name>
      <phone>870-935-6729</phone>
      <email>krubino@stbheart.com</email>
    </contact>
    <investigator>
      <last_name>Barry Tedder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arkansas Heart Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of California San Diego (UCSD)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bahman Ghannadian, MD</last_name>
      <phone>858-246-2360</phone>
      <email>bghannadian@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Mitul Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advocate Christ Hospital and Medical Center</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Doherty, RN</last_name>
      <phone>708-684-4618</phone>
      <email>christopher.doherty@advocatehealth.com</email>
    </contact>
    <investigator>
      <last_name>Jaafer Golzar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baton Rouge General Medical Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacie LaPrarie, RN</last_name>
      <phone>225-237-1673</phone>
      <email>Stacie.laprarie@brgeneral.org</email>
    </contact>
    <contact_backup>
      <last_name>Jane Byrne</last_name>
      <phone>225-237-1674</phone>
      <email>jane.byrne@brgeneral.org&quot;</email>
    </contact_backup>
    <investigator>
      <last_name>Glen Schwartzberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Missouri</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Akers, LPN</last_name>
      <phone>573-882-0177</phone>
      <email>akersji@health.missouri.edu</email>
    </contact>
    <investigator>
      <last_name>Todd Vogel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deborah Heart and Lung Center</name>
      <address>
        <city>Browns Mills</city>
        <state>New Jersey</state>
        <zip>08015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Dewey, RN</last_name>
      <phone>609-893-1200</phone>
      <phone_ext>5023</phone_ext>
      <email>deweyl@deborah.org</email>
    </contact>
    <investigator>
      <last_name>Vincent Varghese, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>TriHealth-Hatton Research Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Reid, MSN, RN, CCRC</last_name>
      <phone>(513)862-5124</phone>
      <email>lori_reid@trihealth.com</email>
    </contact>
    <investigator>
      <last_name>Patrick Muck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dayton Heart Center</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Weller, RN, CCRC</last_name>
      <phone>937-276-8784</phone>
      <phone_ext>3187</phone_ext>
      <email>cweller@premierhealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Jeff Gluck, PHS</last_name>
      <phone>937-276-8784</phone>
      <phone_ext>3152</phone_ext>
      <email>jfgluck@premierhealth.com</email>
    </contact_backup>
    <investigator>
      <last_name>Gary J. Fishbein, MD, FACC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Einstein Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Murphy</last_name>
      <phone>215-456-1959</phone>
      <email>MurphyRa@einstein.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kinnari Murthy, MPH</last_name>
      <phone>215-456-6736</phone>
      <email>MurthyK@einstein.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Sean Janzer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jon George, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Health Science Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38163</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Hendrix</last_name>
      <phone>901-448-2478</phone>
      <email>chendri6@uthsc.edu</email>
    </contact>
    <investigator>
      <last_name>Dwight Dishmon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Associates of East Texas</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Olson</last_name>
      <phone>903-595-2283</phone>
      <email>eolson@caet.net</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Carr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 12, 2017</study_first_submitted>
  <study_first_submitted_qc>June 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2017</study_first_posted>
  <last_update_submitted>May 24, 2021</last_update_submitted>
  <last_update_submitted_qc>May 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

